Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46

Benzinga Newsdesk www.benzinga.com Positive 90.6%

Neg 0% Neu 0% Pos 90.6%

Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Strong Buy rating and announces Price Target of $46.